Pituitary neuroendocrine tumor is a common intracranial tumor, which can produce excessive hormones to induce systemic disease, or cause headache, dizziness or visual impairment due to tumor mass effect. Diagnostic and prognostic biomarkers are conducive to early detection and surgical resection in early patients. Meanwhile, evaluation of tumor aggressiveness has important clinical significance for patient prognosis and treatment analysis. Non-coding RNA (ncRNA) is an emerging biomarker, which is associated with the occurrence of pituitary tumors and has carcinogenic or tumor suppressive properties. NcRNA can be detected in serum, plasma and other biological fluids, and has the characteristics of low trauma, high sensitivity and specificity. It is expected to provide a new therapeutic target and prognostic evaluation for pituitary neuroendocrine tumors. Therefore, this paper reviews the research progress of ncRNA in pituitary neuroendocrine tumors.